Researchers from Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have discovered novel selective Kv2.1 inhibitors as potential therapeutic candidates for the treatment of ischemic stroke.

Invitae Corp. has entered into a partnership with Bridgebio Pharma Inc. to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.

Inflammatory bowel disease (IBD) is characterized by chronic inflammation of the colon with increased levels of angiogenesis.

The activation of PERK signaling triggers angiogenesis, migration and dissemination of cancer cells, and for that reason, the therapeutic blockade of the PERK pathway is a target to watch in cancer therapy. Researchers from Chongqing Medical University reported on the preclinical efficacy and molecular mechanism of CCT-020312, a selective PERK activator, in prostate cancer models.